Ben is Xconomy's Deputy Biotechnology Editor. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
NinePoint Medical looks to have added roughly $31 million in financing to back its medical imaging technology.
In one of the more dramatic biotech events in recent memory, the FDA convened an advisory panel on Tuesday to weigh the risks and benefits of a drug called drisapersen, which... Read more »
It’s the time of year for Americans to rack up massive bills on shopping sprees, gorge themselves with calories they don’t need, then worry how they’re going to make it all... Read more »
Former Sanofi CEO Chris Viehbacher was handed the keys to a big biotech fund from Gurnet Point Capital a few months ago, and today he announced what he’s doing with it.... Read more »
A slew of companies have gone public amidst gene therapy’s recent renaissance, and technological advances have gotten these types of treatments closer than they’ve ever been to impacting healthcare in the... Read more »
Exosomes were once thought of as cellular garbage bins, bubbles filled with waste and shipped out for elimination. But a more sophisticated view of exosomes—and a better understanding of their biological... Read more »
Two privately held biotechs in the Boston area priced IPOs on Tuesday with similar estimates about their value. One of them hit its mark, thanks to some help from a few... Read more »
People lose their vision most often because, simply speaking, they grow old. But in rare cases, a genetic defect leads to a blindness in children and teenagers called Stargardt disease.... Read more »
Duchenne Muscular Dystrophy is a progressive muscle wasting disease that affects about 300,000 people, primarily boys, around the world. Patients with the disease lose ability to walk by their teens, and... Read more »
Bluebird Bio has helped catalyze gene therapy’s recent renaissance with snippets of human data that hint of a long-lasting, perhaps even one-time fix for a crippling blood disorder known as beta-thalassemia.... Read more »
With biotech stocks well off their highs, it was only a matter of time until someone pulled the trigger on a big buyout. That someone has turned out to be Shire,... Read more »
One thing is becoming clear to companies in today’s biotech IPO market: Don’t expect the market value you would’ve gotten a year ago.
San Francisco-based MyoKardia was the latest example. The... Read more »
It’s hard enough to successfully create and sell a biotech company, let alone strike gold twice or more on the same group of assets. But that’s the type of thing Taris... Read more »
There’s still got a long way to go before we know if the landmark gene editing system known as CRISPR-Cas9 can really change how diseases are treated. But big biotech companies... Read more »
There was a loud cheer in New York this week—originating from Queens, to be exact—and it had nothing to do with biotech. The New York Mets, for many years Big Apple... Read more »
Moderna Therapeutics remains the Boston area’s most mysterious, yet well-capitalized private biotech, with more than $800 million to play with. And while it’s still unclear just what type of progress the... Read more »
The sentiment for biotechs trying to go public these days continues to be lukewarm. Witness Dimension Therapeutics, which couldn’t hit its IPO pricing goal despite a cadre of big name investors... Read more »
Biogen’s rise and fall this year has been symbolic of the sector’s bull run and recent retreat, which is why all eyes were squarely on the Cambridge, MA-based company’s latest sales... Read more »
March 31, 2016
© 2007-2016, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.